$NRSN News

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52

NeuroSense Provides Business Update and Progress for the First Half of 2026

NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

NeuroSense Therapeutics Announces 1-For-20 Reverse Stock Split, Effective Sept. 14

HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval

NeuroSense Issues CEO Letter to Shareholders

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"